Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays.

Autor: Banerjee A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India., Ray A; Centre for Research in Nanotechnology & Science (CRNTS), Indian Institute of Technology Bombay, Powai, Mumbai, India., Barpanda A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India., Dash A; Miranda House, University of Delhi, University Enclave, New Delhi, Delhi, India., Gupta I; Department of Biotechnology Engineering, University Institute of Engineering and Technology, Panjab University, Chandigarh, India., Nissa MU; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India., Zhu H; Department of Pharmacology and Molecular Sciences/High-Throughput Biology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Shah A; Department of Neurosurgery at King Edward Memorial Hospital and Seth G. S. Medical College, Parel, Mumbai, India., Duttagupta SP; Department of Electrical Engineering, Indian Institute of Technology Bombay, Powai, Mumbai, India., Goel A; Department of Neurosurgery at King Edward Memorial Hospital and Seth G. S. Medical College, Parel, Mumbai, India., Srivastava S; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Powai, Mumbai, India.
Jazyk: angličtina
Zdroj: Proteomics. Clinical applications [Proteomics Clin Appl] 2022 Nov; Vol. 16 (6), pp. e2100111. Date of Electronic Publication: 2022 Sep 18.
DOI: 10.1002/prca.202100111
Abstrakt: Purpose: To identify the specific diagnostic biomarkers related to pituitary adenomas (PAs), we performed serological antibody profiles for three types of PAs, namely Acromegaly, Cushing's and Nonfunctional Pituitary Adenomas (NFPAs), using the human proteome (HuProt) microarray. This is the first study describing the serum autoantibody profile of PAs.
Experimental Design: We performed serological autoantibody profiling of four healthy controls, four Acromegaly, three Cushing's and three NFPAs patient samples to obtain their autoantibody profiles, which were used for studying expression, interaction and altered biological pathways. Further, significant autoantibodies of PAs were compared with data available for glioma, meningioma and AAgAtlas for their specificity.
Results: Autoantibody profile of PAs led to the identification of differentially expressed significant proteins such as AKNAD1 (AT-Hook Transcription Factor [AKNA] Domain Containing 1), NINJ1 (Nerve injury-induced protein 1), L3HYPDH (Trans-3-hydroxy-L-proline dehydratase), RHOG (Rho-related GTP-binding protein) and PTP4A1 (Protein Tyrosine Phosphatase Type IVA 1) in Acromegaly. Protein ABR (Active breakpoint cluster region-related protein), ST6GALNAC6 (ST6 N-acetylgalactosaminide alpha-2, 6-sialyltransferase 6), NOL3 (Nucleolar protein 3), ANXA8 (Annexin A8) and POLR2H (RNA polymerase II, I and III subunit H) showed an antigenic response in Cushing's patient's serum samples. Protein dipeptidyl peptidase 3 (DPP3) and reticulon-4 (RTN4) exhibited a very high antigenic response in NFPA patients. These proteins hold promise as potential autoantibody biomarkers in PAs.
(© 2022 Wiley-VCH GmbH.)
Databáze: MEDLINE
Externí odkaz: